Company news

Genedx Holdings Corp. (NASDAQ:WGS) news

Genedx Holdings Corp. news releases on 6ix. Latest, Oct 2, 2026: GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care

Genedx Holdings Corp. (NASDAQ:WGS) news

Press releases & updates

GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care

GeneDx Reports Second Quarter 2026 Financial Results

GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026

GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook

GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership

INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025

GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference

JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year

GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

GeneDx to Participate in Upcoming Investor Conferences

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025

GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing

GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer

GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program

GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program

GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025

GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award

GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth

GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference

GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors

Seer Appoints Isaac Ro to its Board of Directors

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025

GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics

GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability

GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

GeneDx Announces Completion of Fabric Genomics Acquisition

GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting

GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis